What is the potential of TOR inhibition for cancer therapy?

Mathematical modelling can be used in cancer therapy

Recombination can drive tumourogenesis

The role of the PI3K and TOR pathways in cancer

Utilising disease heterogeneity and emerging biomarkers to individualise prostate treatment

Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer

Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma

Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets

Regular aspirin use may reduce risk of dying from prostate cancer

Brentuximab vedotin as salvage therapy for men with relapsed germ-cell tumours

Actionable targets in patients with cisplatin-resistant advanced germ cell tumours

Improving cancer control in low-middle income countries and creating a global network of expertise